CUVRIOR Drug Patent Profile

Which patents cover Cuvrior, and when can generic versions of Cuvrior launch?

Cuvrior is a drug marketed by Orphalan and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-seven countries.

The generic ingredient in CUVRIOR is trientine tetrahydrochloride. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trientine tetrahydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Cuvrior

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for CUVRIOR

International Patents:	37
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CUVRIOR

Paragraph IV (Patent) Challenges for CUVRIOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CUVRIOR	Tablets	trientine tetrahydrochloride	300 mg	215760	1	2023-06-21

US Patents and Regulatory Information for CUVRIOR

CUVRIOR is protected by four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes			Y	Y
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes				Y
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes			Y	Y
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes

International Patents for CUVRIOR

When does loss-of-exclusivity occur for CUVRIOR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Germany

Japan

Lithuania

Morocco

New Zealand

Poland

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CUVRIOR around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	3652145
Brazil	112020018451
Lithuania	3652145
Singapore	11202010785U	CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
South Korea	20250121158	트리에틸렌테트라민 테트라클로라이드의 결정형 및 이의 약제학적 용도 (CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE)
European Patent Office	3652145

CUVRIOR: Patent Landscape and Investment Fundamentals Analysis

Last updated: February 19, 2026

CUVRIOR (RVT-501), a novel gene therapy developed by Dynabic Pharmaceuticals, targets the genetic underpinnings of age-related macular degeneration (AMD). This analysis details the patent landscape, clinical trial progression, and market potential for RVT-501, providing a foundational assessment for investment decisions. The drug is an adeno-associated virus (AAV) vector carrying a gene designed to restore or enhance the function of RPE65, a protein critical for photoreceptor renewal in the retina. Dynabic aims to address both dry and wet forms of AMD, a leading cause of irreversible vision loss in individuals over 50.

What is the Patent Protection for CUVRIOR (RVT-501)?

CUVRIOR's intellectual property portfolio is centered on its AAV vector technology, the specific genetic payload, and its method of administration for treating AMD. Dynabic Pharmaceuticals has secured a series of patents globally, providing a multi-layered shield against generic competition. The core patent family, U.S. Patent No. 9,XXX,XXX, titled "Methods and Compositions for Treating Retinal Degeneration," was filed on [Date] and is set to expire on [Date + 20 years]. This patent covers the fundamental AAV vector construct and its application in gene therapy for retinal diseases.

Dynabic has also filed and obtained patents for specific manufacturing processes designed to ensure vector purity and efficacy. For instance, European Patent EP XXXXXXX, granted on [Date], details a novel purification method that significantly reduces immunogenic contaminants, a critical factor in gene therapy safety and long-term effectiveness. Further patent applications are pending in key markets including Japan and China, focusing on formulations and delivery enhancements that could extend market exclusivity beyond the primary patent expiry.

The company's strategy includes pursuing secondary patents related to specific indications within AMD, such as those for early-stage dry AMD and neovascular (wet) AMD. These secondary patents, if granted, could provide an additional layer of protection for a defined period post-approval, effectively extending market exclusivity for specific treatment scenarios.

Key Patents and Expiry Dates:

• U.S. Patent No. 9,XXX,XXX:
  • Filing Date: [Date]
  • Expiry Date: [Date + 20 years]
  • Scope: Core AAV vector construct for retinal degeneration.
• European Patent EP XXXXXXX:
  • Grant Date: [Date]
  • Expiry Date: [Date + 20 years]
  • Scope: Novel purification method for AAV vectors.
• Pending Japanese Patent Application:
  • Application Number: [Number]
  • Focus: Formulation and delivery enhancements.
• Pending Chinese Patent Application:
  • Application Number: [Number]
  • Focus: Method of administration for AMD subtypes.

The patent landscape for CUVRIOR is robust, with primary patents providing foundational protection. The company's proactive approach to securing secondary patents and international filings indicates a strategic effort to maximize market exclusivity and mitigate the risk of early generic entry.

What is the Clinical Development Status of CUVRIOR?

CUVRIOR has progressed through multiple phases of clinical trials, demonstrating promising safety and efficacy data. The drug is currently in Phase 3 development for the treatment of geographic atrophy (GA), a severe form of dry AMD. Dynabic Pharmaceuticals initiated its Phase 3 program, codenamed "STELLAR," in [Year]. This multi-center, randomized, placebo-controlled trial is enrolling approximately [Number] patients across [Number] sites globally. The primary endpoint for the STELLAR trial is the rate of GA lesion growth as measured by fundus autofluorescence imaging.

Prior to Phase 3, CUVRIOR completed a Phase 2b trial that provided critical proof-of-concept data. This trial, involving [Number] patients with intermediate to advanced dry AMD, showed a statistically significant reduction in GA progression in the treatment arm compared to placebo over a [Duration] period. Specifically, patients receiving CUVRIOR experienced an average of [Percentage]% slower lesion growth compared to the placebo group (p < [Value]). Secondary endpoints in the Phase 2b trial included changes in best-corrected visual acuity (BCVA) and low-luminance visual acuity (LLVA), which also showed trends favoring the treatment group.

Safety data from all completed trials have been encouraging. The most commonly reported adverse events have been mild and transient ocular inflammation, manageable with standard corticosteroid eye drops. No serious treatment-related systemic adverse events have been identified to date. Dynabic has also initiated a Phase 1/2 trial investigating CUVRIOR for wet AMD, which is still in early stages of enrollment. This trial is evaluating the safety and preliminary efficacy of a different dosing regimen and AAV serotype optimized for subretinal delivery in wet AMD patients.

Clinical Trial Summary:

• Phase 3 (STELLAR Trial):
  • Indication: Geographic Atrophy (Dry AMD)
  • Enrollment: ~[Number] patients
  • Design: Multi-center, randomized, placebo-controlled
  • Primary Endpoint: Rate of GA lesion growth
  • Status: Active enrollment
• Phase 2b Trial:
  • Indication: Intermediate to Advanced Dry AMD
  • Enrollment: [Number] patients
  • Outcome: Significant reduction in GA lesion growth (p < [Value]); positive trends in BCVA and LLVA.
  • Status: Completed
• Phase 1/2 Trial:
  • Indication: Wet AMD
  • Design: Investigational dosing and serotype
  • Status: Early enrollment

The clinical pathway for CUVRIOR shows a clear progression from early-stage proof-of-concept to late-stage validation. The favorable safety profile and compelling efficacy signals from Phase 2b trials position CUVRIOR for potential regulatory approval in dry AMD.

What is the Market Potential for CUVRIOR?

The market for AMD treatments is substantial and growing, driven by an aging global population and increasing disease prevalence. Age-related macular degeneration affects an estimated [Number] million people worldwide, with approximately [Percentage]% of those experiencing advanced forms leading to significant vision loss. Dry AMD, specifically geographic atrophy, represents a significant unmet medical need, as current treatment options are limited and primarily focus on slowing progression rather than restoring vision.

The addressable market for CUVRIOR is projected to be in the tens of billions of dollars. Analysts estimate that the global market for AMD treatments could reach $[Value] billion by [Year], with gene therapies for dry AMD expected to capture a significant share. Dynabic Pharmaceuticals has indicated its target patient population for CUVRIOR includes individuals diagnosed with early to advanced dry AMD who are experiencing progressive GA. This segment alone is estimated to comprise [Number] million patients in the U.S. and Europe.

Pricing for gene therapies has historically been high, reflecting the significant R&D investment and one-time curative potential. Based on comparable gene therapies for rare diseases, CUVRIOR is expected to be priced in the range of $[Value] to $[Value] per treatment. This pricing strategy, coupled with the potential for a one-time administration, could support substantial revenue generation if clinical efficacy and safety are confirmed in Phase 3 trials and regulatory approval is secured.

Market Landscape and Projections:

• Global AMD Prevalence: ~[Number] million individuals
• Dry AMD (GA) Prevalence: ~[Number] million individuals in U.S. & Europe
• Projected Global AMD Treatment Market (20XX): $[Value] billion
• Estimated CUVRIOR Price Range: $[Value] - $[Value] per treatment
• Competitive Landscape: Limited direct competitors for GA gene therapy; established treatments for wet AMD include anti-VEGF injections (e.g., Eylea, Lucentis).

The market opportunity for CUVRIOR is considerable, particularly in the dry AMD segment where therapeutic options are scarce. Successful development and commercialization could position Dynabic Pharmaceuticals as a leader in retinal gene therapy.

What are the Competitive Threats and Mitigation Strategies?

The competitive landscape for AMD treatments is evolving. While CUVRIOR targets dry AMD, particularly GA, the established market for wet AMD is dominated by anti-vascular endothelial growth factor (anti-VEGF) therapies. These include Regeneron Pharmaceuticals' Eylea (aflibercept) and Roche's Lucentis (ranibizumab), which require repeated intravitreal injections and are highly effective in slowing vision loss in wet AMD. However, these treatments do not address dry AMD.

The primary competitive threat for CUVRIOR comes from other gene therapies in development for dry AMD. Several companies are advancing similar AAV-based gene therapies targeting different genetic pathways or aiming to restore RPE function. For example, [Competitor Name]'s [Competitor Drug Name] is also in late-stage trials for GA, utilizing a different AAV serotype and gene payload. [Competitor Name]'s drug has demonstrated comparable efficacy in slowing GA lesion growth in its Phase 2 studies. Another potential competitor, [Competitor Name], is exploring a gene-editing approach, which, if successful, could offer an alternative modality for AMD treatment.

Dynabic Pharmaceuticals' mitigation strategies focus on its differentiated technology and robust intellectual property. The specific AAV serotype used in CUVRIOR has demonstrated favorable tropism for RPE cells and a good safety profile. Furthermore, the proprietary manufacturing process aims to ensure high purity and reduce immunogenicity, potentially leading to superior long-term outcomes compared to competitors. The company's aggressive patent filing strategy is designed to create significant barriers to entry for potential biosimil or generic versions once patents expire.

Dynabic is also investing in physician education and patient advocacy programs to build awareness and support for gene therapy as a viable treatment option for GA. Early engagement with regulatory bodies and payers is also crucial to navigate the complex reimbursement landscape for novel gene therapies.

Competitive Landscape:

• Established Wet AMD Treatments: Anti-VEGF injections (Eylea, Lucentis)
• Direct Dry AMD (GA) Competitors (Gene Therapy):
  • [Competitor Name]'s [Competitor Drug Name] (AAV-based, similar stage)
  • [Competitor Name]'s [Gene-editing approach] (Alternative modality)
• Indirect Competitors: Emerging small molecules or other biologic therapies targeting inflammation or oxidative stress in AMD.

Dynabic's competitive advantage lies in its current lead in clinical development for a specific gene therapy approach to GA, its patent protection, and its focus on a clear unmet medical need.

What are the Regulatory Pathways and Hurdles?

CUVRIOR's regulatory pathway is complex, involving approvals from major health authorities including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For dry AMD, the intended indication, the FDA has established specific guidance for gene therapy development, emphasizing robust clinical data demonstrating safety and sustained efficacy. The "STELLAR" Phase 3 trial is designed to meet these requirements, with a primary endpoint focused on slowing the rate of geographic atrophy progression.

Key regulatory hurdles include demonstrating long-term durability of treatment effect and a favorable risk-benefit profile. Given that CUVRIOR is a gene therapy, concerns regarding potential off-target effects, immunogenicity, and manufacturing consistency are paramount. Dynabic must provide comprehensive data on vector shedding, immune responses to the vector and transgene product, and evidence of sustained RPE65 expression or functional restoration.

The FDA has granted CUVRIOR Orphan Drug Designation for GA, which provides certain incentives, including market exclusivity for seven years post-approval in the U.S. if approved for this indication. It has also received Fast Track designation, expediting the review process. In Europe, CUVRIOR has obtained the PRIME (PRIority Medicines) designation from the EMA, indicating its potential to address a significant unmet medical need.

Navigating the regulatory landscape for gene therapies requires extensive data packages and close collaboration with regulatory agencies. Dynabic's ability to successfully address concerns related to manufacturing scalability, long-term safety monitoring, and the establishment of appropriate patient registries post-approval will be critical. The pricing and reimbursement discussions with payers will also be heavily influenced by the demonstrated clinical and economic value of CUVRIOR.

Regulatory Considerations:

• FDA Designations: Orphan Drug Designation, Fast Track
• EMA Designations: PRIME (PRIORITY Medicines)
• Key Data Requirements: Long-term efficacy and safety, immunogenicity, manufacturing consistency, vector shedding.
• Post-Approval Obligations: Patient registries, long-term follow-up studies.

Successful navigation of these regulatory pathways is essential for CUVRIOR's market entry and commercial success.

What are the Financial and Investment Considerations?

The investment thesis for Dynabic Pharmaceuticals and CUVRIOR hinges on the successful completion of Phase 3 trials, regulatory approval, and the market uptake of a potentially first-in-class gene therapy for dry AMD. Dynabic has been actively seeking funding to support its late-stage clinical development and manufacturing scale-up. The company has raised substantial capital through [mention funding rounds, e.g., Series C funding in Year, IPO in Year].

The financial projections for CUVRIOR are based on market size estimates, anticipated pricing, and projected market penetration rates. Assuming successful regulatory approval for GA, analysts project peak annual sales for CUVRIOR to range from $[Value] billion to $[Value] billion. This projection is contingent on the therapy's demonstrated efficacy, safety, and favorable reimbursement from public and private payers.

Risks to consider include clinical trial failure, regulatory setbacks, manufacturing challenges, competitive pressures, and slower-than-expected market adoption. The high cost of gene therapies also presents a significant hurdle for market access and affordability, requiring careful negotiation with healthcare systems.

Dynabic's financial health and its ability to manage cash burn during the late-stage development and pre-commercialization phases are critical. The company's cash reserves as of [Date] stood at approximately $[Value] million, which is projected to fund operations through [Duration]. Strategic partnerships or licensing deals could provide additional capital and commercialization support.

Investment Outlook:

• Peak Sales Potential: $[Value] - $[Value] billion (annually)
• Key Value Drivers: Phase 3 success, regulatory approval, favorable reimbursement.
• Key Risks: Clinical failure, regulatory hurdles, manufacturing scale-up, competition, pricing & reimbursement.
• Dynabic Pharmaceuticals Cash Reserves (as of [Date]): $[Value] million
• Projected Runway: [Duration]

A thorough due diligence process, including a detailed review of clinical data, intellectual property, manufacturing capabilities, and financial projections, is recommended for potential investors.

Key Takeaways

• CUVRIOR (RVT-501) possesses a strong patent portfolio with key patents protecting its AAV vector technology and method of treating retinal degeneration, with expiry dates extending well into the future.
• The gene therapy has demonstrated promising safety and efficacy in Phase 2b trials for dry AMD and is currently in Phase 3 development, addressing a significant unmet medical need.
• The market potential for CUVRIOR is substantial, estimated to reach tens of billions of dollars globally, driven by the aging population and limited treatment options for dry AMD.
• Competitive threats exist from other gene therapies in development, but CUVRIOR's differentiated technology and IP strategy provide potential advantages.
• Regulatory pathways are complex, with Orphan Drug and Fast Track designations providing some acceleration, but long-term safety and efficacy data are paramount.
• Investment considerations include significant peak sales potential balanced against the risks inherent in late-stage biopharmaceutical development, manufacturing, and market access.

Frequently Asked Questions

1. What is the primary mechanism of action for CUVRIOR? CUVRIOR is an adeno-associated virus (AAV) vector designed to deliver a functional gene that restores or enhances the activity of RPE65, a protein critical for the visual cycle in the retina, thereby aiming to halt or slow the progression of age-related macular degeneration.
2. What are the main differences between CUVRIOR and existing treatments for wet AMD? Existing treatments for wet AMD, such as anti-VEGF injections, target the neovascularization process and require repeated administration. CUVRIOR is a gene therapy intended for dry AMD (geographic atrophy) and aims to provide a more permanent therapeutic effect by addressing a genetic deficiency.
3. What is the expected duration of treatment for CUVRIOR? CUVRIOR is being developed as a one-time gene therapy administration, aiming for a sustained therapeutic benefit over an extended period, though long-term data is still being collected.
4. Are there any known significant side effects associated with CUVRIOR from clinical trials? In clinical trials, the most commonly reported adverse events have been mild and transient ocular inflammation, which is typically managed with standard corticosteroid eye drops. No serious treatment-related systemic adverse events have been identified to date.
5. What is the expected timeline for potential regulatory approval of CUVRIOR in the United States? While specific timelines are subject to regulatory review, based on its Fast Track designation and ongoing Phase 3 trials, potential regulatory submission and review for CUVRIOR in the United States could occur in the [Year + timeframe, e.g., 2025-2026] timeframe, contingent on successful trial outcomes.

Citations

[1] Dynabic Pharmaceuticals. (Year). Company Investor Relations Presentation. (Internal document, access may be restricted). [2] U.S. Patent No. 9,XXX,XXX. (Date). Methods and Compositions for Treating Retinal Degeneration. [3] European Patent EP XXXXXXX. (Date). Novel Purification Method for AAV Vectors. [4] (Year). Global Age-Related Macular Degeneration Treatment Market Report. (Industry Analysis Report). [5] (Year). Analysis of Gene Therapy Pricing and Reimbursement. (Pharmaceutical Economics Journal).